Erratum: Treatment of immobilization-related hypercalcaemia with denosumab (Clinical Kidney Journal (2012) 5 (491-495) DOI: 10.1093/ckj/sfs133);Treatment of immobilization-related hypercalcaemia with denosumab

Clinical Kidney Journal

Volumn 5, Issue 6, 2012, Pages 491-495

  Malberti, Fabio ^a  

^a Cremona General Hospital   (Italy)

Author keywords

denosumab; hypercalcaemia; immobilization related hypercalcaemia; RANKL

Indexed keywords

DENOSUMAB;

HUMAN; HYPERCALCEMIA; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 84870553397     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft013     Document Type: Erratum

References (52)

1. Frolich A. Prevalence of hypercalcemia in normal and hospitalized populations. Dan Med Bull 1998; 45: 436-439 (Pubitemid 28419433)
2. Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res 1991; 6(Suppl 2): S51-S59
3. Khairallah W, Fawaz A, Brown EM et al. Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol 2007; 3: 397-404 (Pubitemid 46987806)
4. de Beus E, Boer WH. Denosumab for treatment of immobilization- related hypercalcemia in a patient with advanced renal failure. Clin Kidney J 2012; 5: 566-571
5. Stewart AF, Adler M, Byers CM et al. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982; 306: 1136-1140 (Pubitemid 12161336)
6. Meythaler JM, Korkor AB, Nanda T et al. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med 1986; 146: 1567-1571 (Pubitemid 16072328)
7. Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999; 80: 998-1000 (Pubitemid 29439309)
8. Gopal H, Sklar AH, Sherrard DJ. Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease. Am J Kidney Dis 2000; 35: 969-972 (Pubitemid 30238214)
9. Kodama H, Nose M, Niida S et al. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991; 173: 1291-1294
10. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253 (Pubitemid 32646379)
11. Roodman GD. Mechanism of bone metastasis. N Engl J Med 2004; 350: 1655-1664
12. Aubin JE. Bone stem cells. J Cell Biochem Suppl 1998; 30-31: 73-82 (Pubitemid 29028728)
13. Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 2002; 8: 340-345 (Pubitemid 34733388)
14. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764 (Pubitemid 27516178)
15. Mundy GR, Chen D, Zhao M et al. Growth regulatory factors and bone. Rev Endocr Metab Disord 2001; 2: 105-115 (Pubitemid 33643897)
16. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319 (Pubitemid 27199902)
17. Burges TL, Qian Y, Kaufman S et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol 1999; 145: 527-538 (Pubitemid 29215717)
18. Min H, Morony S, Sarosi I et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474 (Pubitemid 30666247)
19. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis inmice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615 (Pubitemid 28418439)
20. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412-1224
21. Eghbali-Fatourechi G, Khosla S, Sanyal A et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111: 1221-1230 (Pubitemid 36519939)
22. von Tirpitz C, Epp S, Klaus J et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol 2003; 15: 1165-1170 (Pubitemid 38174839)
23. Mori H, Kitazawa R, Mizuki S et al. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol 2002; 117: 283-292 (Pubitemid 34253333)
24. Standal T, Seidel C, Hjertner Oø et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100: 3002-3007
25. Michigami T, Ihara-Watanabe M, Yamazaki M et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001; 61: 1637-1644 (Pubitemid 34292599)
26. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004; 4: 268-275 (Pubitemid 39504354)
27. Xiong J, Onal M, Jilka RL et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17: 1235-1241
28. Rubin J, Murphy T, Nanes MS et al. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells. Am J Physiol Cell Physiol 2000; 278: C1126-C1132 (Pubitemid 30432396)
29. Mochizuki S, Fujise N, Higashio K et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. J Bone Miner Metab 2002; 20: 14-20 (Pubitemid 34101090)
30. Tsourdi E, Rachner TD, Rauner M et al. Denosumab for bone disease: translating bone biology into target therapy. Eur J Endocrinol 2011; 165: 833-840
31. Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, 96: 972-980
32. Body JJ, Lipton A, Gralow J et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 25: 440-446
33. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97: 2692-2696 (Pubitemid 26197084)
34. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373-379
35. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29: S12-S18
36. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567 (Pubitemid 32112871)
37. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85 (Pubitemid 26092586)
38. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289 (Pubitemid 36714182)
39. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphsphonates. Ann Oncol 2006; 17: 897-907 (Pubitemid 43785797)
40. Berenson J, Hirschberg R. Safety and convenience of a 15- minute infusion of zoledronic acid. The Oncologist 2004; 9: 319-329 (Pubitemid 38756880)
41. Guarneri V, Donati S, Nicolini M et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842-848 (Pubitemid 43152702)
42. Block GA, Bone HG, Fang L et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479
43. Tabrizi MA, Tseng CM, Roskos LE et al. Elimination mechanism of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81-88 (Pubitemid 43227856)
44. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228 (Pubitemid 43342512)
45. Yonemori K, Fujihiro Y, Minami H et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008; 99: 1237-1242 (Pubitemid 351676637)
46. Morony S, Warmington K, Adamu S et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 3235-3243 (Pubitemid 41058092)
47. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-5139
48. Henry DH, Costa L, Goldwasser F et al. Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 1125-1132
49. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
50. Papapoulos S, Chapurlat R, Libanati C et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2011; 27: 694-701
51. Jamal SA, Ljunggren O, Stehman-Breen C et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011; 26: 1829-1835
52. Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012; 6: 89-99